Gomez DR, et al. - Since patients with oligometastatic non–small-cell lung cancer (NSCLC) that did not progress following front-line systemic treatment experienced improved progression-free survival (PFS) and delayed new disease when given local consolidative therapy (LCT) with radiotherapy or surgery, researchers now focused on longer-term overall survival (OS) outcomes and additional secondary end points in this multicenter, randomized, phase II trial. Patients received maintenance therapy or observation (MT/O) or LCT to all active disease sites, via randomization (1:1). Findings revealed prolonged PFS and OS in relation to LCT vs MT/O in patients with oligometastatic NSCLC that did not progress following front-line systemic therapy.